section name header

Pronunciation

thee-OFF-i-lin

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: xanthines

Indications

REMS


Action

  • Inhibit phosphodiesterase, producing increased tissue concentrations of cyclic adenosine monophosphate (cAMP). Increased levels of cAMP result in:
    • Bronchodilation,
    • CNS stimulation,
    • Positive inotropic and chronotropic effects,
    • Diuresis,
    • Gastric acid secretion.
Therapeutic effects:
  • Bronchodilation.

Pharmacokinetics

Absorption: Well absorbed from PO dosage forms; absorption from extended-release dosage forms is slow but complete. IV administration results in complete bioavailability.

Distribution: Widely distributed; does not distribute into adipose tissue.

Metabolism/Excretion: 90% metabolized by the liver to several metabolites (including the active metabolites, caffeine, and 3-methylxanthine); metabolites are renally excreted; 10% excreted unchanged by the kidneys.

Half-Life: Premature infants: 20–30 hr; Term infants: 11–25 hr; Children 1–4 yr: 3.4 hr; Children 6–17 yr: 3.7 hr; Adults: 9–10 hr ( in patients >60 yr, patients with HF or liver disease; in cigarette smokers ).

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
POrapid1–2 hr6 hr
PO-ERdelayed4–8 hr8–24 hr
IVrapidend of infusion6–8 hr



Provided that a loading dose has been given and steady-state blood levels exist.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Elixophyllin, Theo-24, Theochron

Canadian Brand Names

Theo ER